{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:11:44Z","timestamp":1763705504210,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.clbc.2018.07.022","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T23:01:22Z","timestamp":1533337282000},"page":"e759-e765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Erlotinib for Progressive Brain and Leptomeningeal Metastases From HER2-positive Breast Cancer After Treatment Failure With Trastuzumab and Lapatinib: Experience and Review of Literature"],"prefix":"10.1016","volume":"18","author":[{"given":"Guanghui","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangying","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2018.07.022_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.17116\/neiro201680183-87","article-title":"[A clinical case of combined treatment of a patient with breast cancer and metastases to the brain and meninges]","volume":"80","author":"Moskvina","year":"2016","journal-title":"Zh Vopr Neirokhir Im N N Burdenko"},{"key":"10.1016\/j.clbc.2018.07.022_bib2","first-page":"117","article-title":"Leptomeningeal metastases in breast cancer","volume":"3","author":"Scott","year":"2013","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clbc.2018.07.022_bib3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-010-0524-y","article-title":"Meningeal carcinomatosis in breast cancer: prognostic factors and outcome","volume":"104","author":"de Azevedo","year":"2011","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clbc.2018.07.022_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1684\/bdc.2011.1341","article-title":"[Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?]","volume":"98","author":"Gutierrez","year":"2011","journal-title":"Bull Cancer"},{"key":"10.1016\/j.clbc.2018.07.022_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-007-9340-4","article-title":"Breast cancer leptomeningeal metastasis\u2013the role of multimodality treatment","volume":"84","author":"Rudnicka","year":"2007","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clbc.2018.07.022_bib6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s12032-012-0408-4","article-title":"Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival","volume":"30","author":"Niwinska","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.clbc.2018.07.022_bib7","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.ejca.2004.08.012","article-title":"The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study","volume":"40","author":"Boogerd","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2018.07.022_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-013-1092-8","article-title":"A\u00a0retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer","volume":"113","author":"Le Rhun","year":"2013","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clbc.2018.07.022_bib9","first-page":"201","article-title":"Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience","volume":"72","author":"Jo","year":"2013","journal-title":"Cancer\u00a0Chemother\u00a0Pharmacol"},{"key":"10.1016\/j.clbc.2018.07.022_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2004.05.008","article-title":"Leptomeningeal metastasis: survival and prognostic factors in 155 patients","volume":"223","author":"Herrlinger","year":"2004","journal-title":"J\u00a0Neurol Sci"},{"issue":"Suppl 4","key":"10.1016\/j.clbc.2018.07.022_bib11","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2018.07.022_bib12","first-page":"1075","article-title":"Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival","volume":"107","author":"Yap","year":"2012","journal-title":"Br\u00a0J\u00a0Cancer"},{"key":"10.1016\/j.clbc.2018.07.022_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","article-title":"Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis","volume":"95","author":"Bonneau","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2018.07.022_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdu486","article-title":"Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA","volume":"26","author":"Krop","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2018.07.022_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-205680","article-title":"Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases","volume":"2014","author":"Torres","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clbc.2018.07.022_bib16","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2018.07.022_bib17","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S1470-2045(15)00373-3","volume":"16","author":"Cortes","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2018.07.022_bib18","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2015.63.0343","article-title":"Translational Breast Cancer Research Consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases","volume":"34","author":"Freedman","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.07.022_bib19","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2018.07.022_bib20","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2018.07.022_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clbc.2018.07.022_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13550-015-0082-6","article-title":"(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients","volume":"5","author":"Kurihara","year":"2015","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.clbc.2018.07.022_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11060-007-9420-5","article-title":"Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer","volume":"85","author":"Bartsch","year":"2007","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clbc.2018.07.022_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1124\/dmd.108.024646","volume":"37","author":"Polli","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clbc.2018.07.022_bib25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10585-015-9740-3","article-title":"Activity of T-DM1 in Her2-positive breast cancer brain metastases","volume":"32","author":"Bartsch","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clbc.2018.07.022_bib26","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10549-012-2003-y","article-title":"A\u00a0phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab","volume":"133","author":"Lin","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2018.07.022_bib27","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.2014.56.3809","article-title":"Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer","volume":"32","author":"Saura","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.07.022_bib28","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2016.0237","article-title":"Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial","volume":"2","author":"Awada","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2018.07.022_bib29","doi-asserted-by":"crossref","first-page":"e0125232","DOI":"10.1371\/journal.pone.0125232","article-title":"Using the MCF10A\/MCF10CA1a breast cancer progression cell line model to investigate the effect of active, mutant forms of EGFR in breast cancer development and treatment using gefitinib","volume":"10","author":"Bessette","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2018.07.022_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2018.07.022_bib31","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2018.07.022_bib32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.07.022_bib33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2014.222679","article-title":"Circulating tumor DNA as a liquid biopsy for cancer","volume":"61","author":"Heitzer","year":"2014","journal-title":"Clin Chem"},{"key":"10.1016\/j.clbc.2018.07.022_bib34","doi-asserted-by":"crossref","first-page":"224ra224","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clbc.2018.07.022_bib35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature12065","article-title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2018.07.022_bib36","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat Commun"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918303847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918303847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:20:09Z","timestamp":1761513609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820918303847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1526820918303847"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2018.07.022","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erlotinib for Progressive Brain and Leptomeningeal Metastases From HER2-positive Breast Cancer After Treatment Failure With Trastuzumab and Lapatinib: Experience and Review of Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2018.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}